Publications by authors named "Katherine Matthay"

Claim this Profile
A
Adaptive Clinical Neuroblastoma Risk Groups-Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project.
Wendy B London, Gabriela Villanueva, Derek Shyr, Jaques van Heerden, Soad Fuentes-Alabi, Katherine K Matthay

JCO Glob Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
Thomas Cash, Araz Marachelian, Steven G DuBois, Yueh-Yun Chi, Anahit Baregamyan, Katherine K Matthay

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International neuroblastoma risk group consortium: a model of a networking for rare cancers.
Susan L Cohn, Wendy B London, Gudrun Schleiermacher, Lucas Moreno, Inge M Ambros, Katherine K Matthay

J Natl Cancer Inst· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editor's Note: Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma.
Louis Chesler, Chris Schlieve, David D Goldenberg, Anna Kenney, Grace Kim, Katherine K Matthay

Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.
Erin K Barr, Arlene Naranjo, Clare J Twist, Sheena C Tenney, Mary Lou Schmidt, Katherine K Matthay

Pediatr Blood Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late cognitive and adaptive outcomes of patients with neuroblastoma-associated opsoclonus-myoclonus-ataxia-syndrome: A report from the Children's Oncology Group.
Prerna Kumar, Victoria W Willard, Leanne Embry, Arlene Naranjo, Brian LaBarre, Katherine K Matthay

Pediatr Blood Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with I-MIBG therapy in high-risk neuroblastoma.
Prerna Kumar, Jessica Koach, Erin Nekritz, Sucheta Mukherjee, Benjamin S Braun, Katherine K Matthay

EJNMMI Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric neuroblastoma with intraspinal extension: the role of surgical management.
Diana Chang, Taemin Oh, Jarod L Roland, Katherine K Matthay, Kieuhoa T Vo

J Neurosurg Pediatr· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.
Michael D Hogarty, David S Ziegler, Andrea Franson, Yueh-Yun Chi, Denice Tsao-Wei, Katherine K Matthay

Br J Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALK upregulates POSTN and WNT signaling to drive neuroblastoma.
Miller Huang, Wanqi Fang, Alvin Farrel, Linwei Li, Antonios Chronopoulos, Katherine K Matthay

Cell Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to I-MIBG in patients with relapsed/refractory neuroblastoma.
Vandana Batra, Ajami Gikandi, Bruce Pawel, Daniel Martinez, M Meaghan Granger, Katherine K Matthay

Pediatr Blood Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aurora Kinase A inhibition enhances DNA damage and tumor cell death with I-MIBG therapy in high-risk neuroblastoma.
Prerna Kumar, Jessica Koach, Erin Nekritz, Sucheta Mukherjee, Benjamin S Braun, Katherine K Matthay

Res Sq· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.
Keri A Streby, Marguerite T Parisi, Barry L Shulkin, Brian LaBarre, Rochelle Bagatell, Katherine K Matthay

Pediatr Blood Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma.
Miriam I Rosenberg, Erez Greenstein, Martin Buchkovich, Ayelet Peres, Eric Santoni-Rugiu, Katherine K Matthay

Cell Rep· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Kelly C Goldsmith, Julie R Park, Kimberly Kayser, Jemily Malvar, Yueh-Yun Chi, Katherine K Matthay

Nat Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of Radiation Biomarkers in a Randomized Phase II Study of I-MIBG With or Without Radiation Sensitizers for Relapsed or Refractory Neuroblastoma.
Kevin Campbell, Susan Groshen, Angela C Evans, Stephen Wilson, Aimy Sebastian, Katherine K Matthay

Int J Radiat Oncol Biol Phys· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, Arlene Naranjo, Wendy B London, Katherine K Matthay

J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
Julie R Park, Judith G Villablanca, Barbara Hero, Brian H Kushner, Keith Wheatley, Katherine K Matthay

Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pattern and predictors of sites of relapse in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Kieuhoa T Vo, Steven G DuBois, John Neuhaus, Steve E Braunstein, Brent R Weil, Katherine K Matthay

Pediatr Blood Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing therapy for neuroblastoma.
Bo Qiu, Katherine K Matthay

Nat Rev Clin Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countries.
Katherine K Matthay, Jennifer Hylton, Neela Penumarthy, Mohammed Khattab, Shui Yen Soh

Pediatr Blood Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anatomic patterns of relapse and progression following treatment with I-MIBG in relapsed or refractory neuroblastoma.
Rotem Fishel Ben Kenan, Alexei L Polishchuk, Randall A Hawkins, Steve E Braunstein, Katherine K Matthay

Pediatr Blood Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral Blood Transcript Signatures after Internal 131I-mIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures.
Angela C Evans, Tim Setzkorn, David A Edmondson, Haley Segelke, Paul F Wilson, Katherine K Matthay

Radiat Res· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
Steven G DuBois, M Meaghan Granger, Susan Groshen, Denice Tsao-Wei, Lingyun Ji, Katherine K Matthay

J Clin Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A safety and feasibility trial of I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study.
Brian D Weiss, Gregory Yanik, Arlene Naranjo, Fan F Zhang, Wendy Fitzgerald, Katherine K Matthay

Pediatr Blood Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis